Zura Bio (ZURA) Projected to Post Quarterly Earnings on Wednesday

Zura Bio (NASDAQ:ZURA) is projected to issue its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 9:30 AM ET.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.31). On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Price Performance

ZURA stock opened at $5.38 on Wednesday. The firm has a 50 day simple moving average of $6.18 and a two-hundred day simple moving average of $4.61. The stock has a market cap of $349.81 million, a PE ratio of -5.08 and a beta of 0.18. Zura Bio has a one year low of $0.97 and a one year high of $7.44.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Chardan Capital upped their target price on shares of Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Wedbush started coverage on Zura Bio in a report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Oppenheimer decreased their price objective on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Friday, March 20th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.60.

Insider Transactions at Zura Bio

In other news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the business’s stock in a transaction on Thursday, February 26th. The shares were acquired at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the acquisition, the insider directly owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. The trade was a 43.93% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 22.10% of the stock is currently owned by company insiders.

Institutional Trading of Zura Bio

A number of institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after purchasing an additional 2,052,732 shares during the period. Siren L.L.C. purchased a new stake in Zura Bio in the 4th quarter worth approximately $6,812,000. VR Adviser LLC grew its position in shares of Zura Bio by 15.4% in the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after buying an additional 713,899 shares during the last quarter. Braidwell LP grew its position in shares of Zura Bio by 28.6% in the 4th quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock worth $16,665,000 after buying an additional 707,583 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Zura Bio by 228.5% during the fourth quarter. Marshall Wace LLP now owns 877,763 shares of the company’s stock valued at $4,599,000 after buying an additional 610,563 shares during the period. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.